查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1522146

非酒精性脂肪性肝炎治療市場 - 全球產業規模、佔有率、趨勢、機會和預測，按藥物類型、最終用戶、地區和競爭細分，2019-2029F

Non-Alcoholic Steatohepatitis Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Type, By End-User, By Region & Competition, 2019-2029F
出版日期: | 出版商: TechSci Research | 英文 183 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2023 年全球非酒精性脂肪性肝炎治療市場價值為11.5 億美元，預計在預測期內將強勁成長，到2029 年複合年成長率為39.30%。減少疾病進展相關的肝臟發炎和損傷。 NASH 是非酒精性脂肪肝病 (NAFLD) 的一種更高級形式，其特徵是發炎和肝細胞損傷。如果不及時治療，NASH 可能會導致更嚴重的肝臟疾病，例如纖維化（疤痕）、肝硬化（晚期疤痕），甚至肝衰竭。此外，NASH 增加了心血管疾病和糖尿病等其他併發症的風險，並且人們對非酒精性脂肪性肝炎治療相關健康益處的認知的提高預計將對全球市場的成長產生積極影響。

市場概況
預測期 2025-2029
2023 年市場規模 11.5億美元
2029 年市場規模 84.2億美元
2024-2029 年複合年成長率 39.30%
成長最快的細分市場 維生素E和吡格列酮部分
最大的市場 北美洲

NASH 治療的主要目的是減少肝臟發生的發炎和損傷。這有助於減緩或阻止疾病進展到更嚴重的階段，例如纖維化和肝硬化。纖維化是肝臟中疤痕組織的積累，而肝硬化是疤痕形成的晚期階段。 NASH 治療旨在預防或最大程度地減少纖維化和肝硬化的發展，因為這些情況可能導致嚴重的肝功能障礙和併發症。許多 NASH 患者也存在胰島素阻抗，並且有罹患第 2 型糖尿病的風險。 NASH 治療通常包括提高胰島素敏感性的干涉措施，這有助於減少肝臟發炎和肝臟脂肪堆積。減重是 NASH 治療的關鍵組成部分，特別是對於超重或肥胖的個體。減輕多餘體重可以改善肝臟健康、胰島素敏感性和整體代謝功能。 NASH 與肥胖、代謝症候群以及第 2 型糖尿病和血脂異常等相關疾病密切相關。 NASH 治療涉及管理這些潛在的危險因素，以改善整體健康並減少對肝臟的影響。

主要市場促進因素

非酒精性脂肪性肝炎 (NASH) 盛行率上升

生活方式的改變和肥胖流行

增加醫療支出

主要市場挑戰

對疾病機制的了解有限

誤診和漏診的風險

缺乏非侵入性診斷工具

主要市場趨勢

臨床試驗的增加

細分市場洞察

藥物類型見解

區域洞察

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：COVID-19 對全球非酒精性脂肪性肝炎治療市場的影響

第 5 章：客戶之聲

第 6 章：全球非酒精性脂肪性肝炎治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依藥物類型（維生素 E 和吡格列酮、奧貝膽酸 (OCA)、拉尼夫拉諾、司馬魯肽、瑞美隆、Aramchol、Cenicriviroc 等）
    • 按最終用戶（醫院藥房、零售和專業藥房、其他）
    • 按地區
    • 按公司分類 (2023)
  • 市場地圖

第 7 章：亞太地區非酒精性脂肪性肝炎治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依藥物類型
    • 按最終用戶
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 澳洲
    • 日本
    • 韓國

第 8 章：歐洲非酒精性脂肪性肝炎治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依藥物類型
    • 按最終用戶
    • 按國家/地區
  • 歐洲：國家分析
    • 法國
    • 德國
    • 西班牙
    • 義大利
    • 英國

第 9 章：北美非酒精性脂肪性肝炎治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依藥物類型
    • 按最終用戶
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第 10 章：南美洲非酒精性脂肪性肝炎治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依藥物類型
    • 按最終用戶
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 11 章：中東和非洲非酒精性脂肪性肝炎治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依藥物類型
    • 按最終用戶
    • 按國家/地區
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 12 章：市場動態

  • 促進要素
  • 挑戰

第 13 章：市場趨勢與發展

  • 最近的發展
  • 產品發布
  • 併購

第 14 章：全球非酒精性脂肪性肝炎治療市場：SWOT 分析

第 15 章：波特的五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代產品的威脅

第 16 章：大環境分析

第17章：競爭格局

  • Intercept Pharmaceuticals Inc
  • Galmed Research & Development Ltd.
  • INVENTIVA SA
  • AbbVie Inc.
  • Galectin Therapeutics Inc.
  • Madrigal Pharmaceuticals Inc.
  • NGM Biopharmaceuticals Inc.
  • Novo Nordisk A/S
  • Bristol Myers Squibb
  • Gilead Sciences Inc

第 18 章：策略建議

簡介目錄
Product Code: 24045

Global Non-Alcoholic Steatohepatitis Treatment Market valued at USD 1.15 billion in 2023 and is anticipated to project robust growth in the forecast period with a CAGR of 39.30% through 2029. Non-Alcoholic Steatohepatitis Treatment is to prevent the progression of the disease and to reduce the associated liver inflammation and damage. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD), characterized by inflammation and liver cell injury. If left untreated, NASH can lead to more serious liver conditions, such as fibrosis (scarring), cirrhosis (advanced scarring), and even liver failure. Additionally, NASH increases the risk of other complications like cardiovascular disease and diabetes, and increased awareness of the health benefits associated with Non-Alcoholic Steatohepatitis Treatment are expected to positively influence the global market growth.

Market Overview
Forecast Period2025-2029
Market Size 2023USD 1.15 Billion
Market Size 2029USD 8.42 Billion
CAGR 2024-202939.30%
Fastest Growing SegmentVitamin E And Pioglitazone Segment
Largest MarketNorth America

The primary aim of NASH treatment is to reduce the inflammation and injury occurring in the liver. This helps to slow down or halt the progression of the disease to more severe stages, such as fibrosis and cirrhosis. Fibrosis is the accumulation of scar tissue in the liver, and cirrhosis is the advanced stage of scarring. NASH treatment aims to prevent or minimize the development of fibrosis and cirrhosis, as these conditions can lead to significant liver dysfunction and complications. Many individuals with NASH also have insulin resistance and are at risk of developing type 2 diabetes. NASH treatment often includes interventions to improve insulin sensitivity, which can help reduce liver inflammation and the accumulation of fat in the liver. Weight loss is a key component of NASH treatment, especially in individuals who are overweight or obese. Losing excess weight can lead to improvements in liver health, insulin sensitivity, and overall metabolic function. NASH is closely associated with obesity, metabolic syndrome, and related conditions like type 2 diabetes and dyslipidaemia. NASH treatment involves managing these underlying risk factors to improve overall health and reduce the impact on the liver.

Key Market Drivers

Rising Prevalence of Non-Alcoholic Steatohepatitis (NASH)

The rising prevalence of Non-Alcoholic Steatohepatitis (NASH) directly contributes to the growth of the global NASH treatment market. NASH is a progressive liver disease characterized by inflammation and liver cell damage, often associated with obesity, insulin resistance, and metabolic syndrome. As the prevalence of NASH increases, the number of individuals diagnosed with the condition also rises. This larger patient population creates a greater demand for effective treatments and therapies to manage the disease. With greater awareness and understanding of NASH among both healthcare professionals and the general population, more cases are being diagnosed. Improved diagnostic methods and guidelines have contributed to earlier and more accurate detection of NASH, leading to increased demand for treatment options. The economic burden of NASH on healthcare systems is substantial due to its potential to progress to advanced liver conditions like fibrosis, cirrhosis, and hepatocellular carcinoma. This drives healthcare providers, governments, and patients to invest in appropriate treatment strategies to prevent disease progression and associated complications.

NASH can lead to a reduced quality of life due to symptoms like fatigue, discomfort, and the psychological impact of a chronic liver condition. Patients are motivated to seek treatment to improve their overall well-being and maintain a higher quality of life. Efforts to increase awareness about NASH, its risk factors, and its potential consequences have led to more individuals seeking medical attention and treatment options. This growing awareness is a key driver behind the increasing prevalence of NASH cases. The global rise in obesity rates and the prevalence of metabolic syndrome, which includes factors like insulin resistance and dyslipidaemia, directly contribute to the increased risk of developing NASH. As these conditions become more common, so does the incidence of NASH.

Lifestyle Changes and Obesity Epidemic

Lifestyle changes and the obesity epidemic play a significant role in driving the growth of the global Non-Alcoholic Steatohepatitis (NASH) treatment market. NASH is closely linked to obesity, insulin resistance, and metabolic syndrome, and the increasing prevalence of these conditions has a direct impact on the demand for NASH treatments. Obesity is a major risk factor for the development of NASH. As the global obesity epidemic continues, more individuals are at a higher risk of developing NASH due to the accumulation of fat in the liver and associated metabolic disturbances. Metabolic syndrome, a cluster of conditions including obesity, high blood pressure, high blood sugar, and abnormal cholesterol levels, is closely linked to NASH. The rising prevalence of metabolic syndrome contributes to the growing incidence of NASH cases. Obesity and sedentary lifestyles are associated with insulin resistance, a condition where the body's cells do not respond effectively to insulin. Insulin resistance is a key factor in the development of NASH, and its prevalence drives the demand for treatments.

Lifestyle changes, including diet modifications and increased physical activity, are crucial components of NASH treatment. As more individuals become aware of the connection between their lifestyle habits and NASH risk, there is a growing demand for interventions that can help manage the condition through lifestyle changes. Weight loss is a primary goal in NASH treatment, as shedding excess weight can lead to improvements in liver health and metabolic function. The obesity epidemic highlights the need for weight management strategies, both as prevention and treatment for NASH. Efforts to address the obesity epidemic and promote healthier lifestyles contribute to increased awareness about NASH and its potential consequences. Public health campaigns aimed at reducing obesity often indirectly contribute to greater awareness of related conditions like NASH.

Increasing Healthcare Expenditure

Increasing healthcare expenditure plays a key role in driving the growth of the global Non-Alcoholic Steatohepatitis (NASH) treatment market. NASH is a progressive liver disease associated with obesity, insulin resistance, and metabolic syndrome. As healthcare expenditures rise, there is a greater focus on addressing chronic diseases like NASH, which require ongoing medical management and treatment. With rising healthcare expenditures, healthcare providers and policymakers recognize the economic and healthcare burden posed by chronic diseases like NASH. This recognition drives the need for investment in research, diagnostics, treatments, and interventions. Increased healthcare spending often leads to improved diagnostic capabilities and greater access to screenings for diseases like NASH. This results in more accurate and earlier detection of NASH cases, driving the demand for appropriate treatment options. Investments in advanced diagnostic technologies, such as imaging techniques and blood tests, enable healthcare professionals to better identify and monitor NASH patients. Accurate diagnosis is crucial for tailoring effective treatment plans. Higher healthcare expenditures can support public health campaigns and patient education initiatives focused on NASH. Increased awareness about the disease encourages individuals to seek medical attention and treatment, contributing to market growth.

Greater healthcare funding can support research efforts to understand the underlying mechanisms of NASH and develop innovative treatments. Pharmaceutical companies receive more financial support for conducting clinical trials and developing new therapies. Increased healthcare spending can lead to improved access to healthcare services, medications, and treatments, making NASH treatments more available and accessible to patients in need. Expanding healthcare infrastructure can facilitate the management of chronic diseases like NASH. This includes the availability of specialized clinics, medical professionals, and resources dedicated to NASH diagnosis and treatment.

Key Market Challenges

Limited Understanding of Disease Mechanisms

The limited understanding of disease mechanisms poses a significant challenge for the global Non-Alcoholic Steatohepatitis (NASH) treatment market. NASH is a complex liver disease characterized by inflammation and liver cell damage, often associated with obesity, insulin resistance, and metabolic syndrome.

Without a comprehensive understanding of the underlying mechanisms driving NASH, it's difficult to develop targeted therapies that address the specific pathways responsible for the disease's development and progression. This can result in a lack of effective treatment options. The diverse nature of NASH, which includes varying degrees of inflammation, fibrosis, and metabolic dysfunction, leads to heterogeneity in patient responses to treatments. A deeper understanding of disease mechanisms could help identify subtypes of NASH and guide personalized treatment approaches.

Developing therapies without a complete understanding of NASH's underlying biology may inadvertently trigger unintended consequences or side effects. This could delay treatment development or even worsen patient outcomes. The lack of clarity about disease mechanisms can extend the drug development process. Researchers may need to conduct more exploratory studies to identify potential therapeutic targets, which can prolong the timeline for bringing new treatments to market. Clinical trials for NASH therapies may have a higher risk of failure if the interventions are not grounded in a deep understanding of disease mechanisms. This can result in resources wasted on unsuccessful trials. This challenge significantly hampers the adoption and usage of such supplements by new customers, ultimately impacting market growth in the forecast period.

Risk of Misdiagnosis and Underdiagnosis

The risk of misdiagnosis and underdiagnosis poses a significant challenge for the global Non-Alcoholic Steatohepatitis (NASH) treatment market. NASH is a liver condition characterized by inflammation and liver cell damage, often associated with obesity, insulin resistance, and metabolic syndrome. Misdiagnosis and underdiagnosis of NASH can lead to delayed or inadequate treatment, impacting patient outcomes and the overall growth of the treatment market. NASH can be asymptomatic, especially in its early stages. Patients may not experience noticeable symptoms, leading to a lack of awareness and delaying diagnosis. This makes it challenging to identify and treat NASH before it progresses to more severe stages.

The symptoms of NASH can overlap with those of other liver conditions, such as alcoholic liver disease, viral hepatitis, and even non-alcoholic fatty liver disease (NAFLD) without inflammation. This similarity can result in misdiagnosis or confusion with other diseases. Unlike certain conditions like diabetes or high blood pressure, routine screening for NASH is not widespread. This means that individuals with risk factors for NASH, such as obesity and metabolic syndrome, might not be tested for the disease, leading to underdiagnosis.

Lack of Non-Invasive Diagnostic Tools

The lack of non-invasive diagnostic tools poses a significant challenge for the global Non-Alcoholic Steatohepatitis (NASH) treatment market. NASH is a liver disease characterized by inflammation and liver cell damage, often associated with obesity, insulin resistance, and metabolic syndrome. Non-invasive diagnostic tools are crucial for accurately diagnosing NASH, assessing disease severity, and monitoring treatment response. liver biopsy is considered the gold standard for diagnosing NASH and evaluating liver fibrosis. However, liver biopsy is an invasive procedure that carries risks, discomfort, and potential complications. Patients and healthcare providers are often hesitant to undergo or recommend liver biopsies due to these factors. Due to the invasive nature of liver biopsy, some patients may be unwilling to undergo the procedure, leading to missed opportunities for diagnosis and disease monitoring. This lack of patient compliance can hinder timely intervention and treatment.

The reliance on liver biopsy can lead to underdiagnosis or misdiagnosis of NASH, especially in cases where patients are unwilling to undergo the procedure. This can result in delayed or inadequate treatment. The lack of non-invasive diagnostic tools limits clinicians' ability to accurately diagnose NASH, assess disease severity, and determine appropriate treatment strategies. This unmet need hampers the development of individualized patient care plans.

Key Market Trends

Rise in Clinical Trials

The rise in clinical trials is a significant trend in the Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market. Clinical trials play a pivotal role in advancing our understanding of NASH, evaluating the safety and efficacy of potential treatments, and contributing to the development of novel therapies. The NASH landscape lacks FDA-approved medications as of my last update in September 2021. The rise in clinical trials indicates a growing interest in developing new therapeutic options. These trials focus on testing various drug candidates with diverse mechanisms of action, including targeting inflammation, fibrosis, metabolism, and other pathways associated with NASH. Clinical trials provide a platform to validate the potential of drug candidates. These trials assess the safety, efficacy, and tolerability of investigational medications under controlled conditions. Positive trial results can lead to regulatory approvals and the introduction of new therapies to the market.

The increasing number of clinical trials indicates a robust pipeline of potential NASH treatments. This pipeline diversity includes different drug classes, combination therapies, and interventions aimed at addressing various disease aspects. A vibrant pipeline reflects the commitment of pharmaceutical companies and researchers to addressing NASH's unmet medical need. Clinical trials contribute to a deeper understanding of NASH's pathophysiology and its response to different interventions. Trials generate valuable data on disease progression, biomarkers, and patient populations, which inform the development of targeted treatments. Clinical trials provide patients with access to innovative therapies and specialized care. Patient participation helps researchers collect critical data, enabling them to refine treatment approaches and gain insights into patient experiences and preferences.

Segmental Insights

Drug Type Insights

Based on the category of Drug Type, the Vitamin E and pioglitazone segment emerged as the dominant player in the global market for Non-Alcoholic Steatohepatitis Treatment in 2023. Vitamin E and pioglitazone were among the drug types explored for the treatment of Non-Alcoholic Steatohepatitis (NASH). Please note that the landscape of NASH treatment is dynamic and constantly evolving.

The Vitamin E is an antioxidant that is believed to help reduce oxidative stress and inflammation in the liver. It has been studied as a potential treatment for NASH due to its ability to counteract oxidative damage. Clinical trials have assessed the use of Vitamin E supplements, specifically alpha tocopherol, for the treatment of NASH. Some trials have shown modest improvements in liver enzymes and histological features of NASH. Vitamin E has been associated with improvements in liver enzymes and histological features of NASH, particularly in individuals with non-diabetic NASH. However, its effectiveness varies, and it might not be suitable for all patient populations. The use of Vitamin E in NASH treatment has been somewhat controversial due to concerns about potential side effects and the variability in treatment response among different patient groups.

Also, the Vitamin E and pioglitazone have shown potential benefits in the treatment of NASH, particularly in specific patient populations. However, it's important to note that neither Vitamin E nor pioglitazone is a definitive or universally effective treatment for NASH. The landscape of NASH treatment continues to evolve, and ongoing research is exploring various drug classes and combination therapies to address the complex pathophysiology of the disease. These factors are expected to drive the growth of this segment.

Regional Insights

North America emerged as the dominant region in the global Non-Alcoholic Steatohepatitis Treatment market in 2023, holding the largest market share in terms of value. North America, particularly the United States, has been facing a significant burden of obesity, type 2 diabetes, and metabolic syndrome - all of which are major risk factors for NASH. The high prevalence of these conditions contributes to a larger pool of individuals at risk of developing NASH.

The region boasts well-developed healthcare systems, including advanced medical facilities, specialized clinics, and access to cutting-edge diagnostic and treatment technologies. This infrastructure facilitates early diagnosis and comprehensive management of NASH. North America is a hub for clinical research and pharmaceutical innovation. Many research institutions, academic centres, and pharmaceutical companies in the region are actively engaged in developing and testing NASH treatments. The United States and Canada have a strong healthcare education system that raises awareness about chronic diseases, including NASH. This heightened awareness can lead to early detection, diagnosis, and treatment initiation. The pharmaceutical industry in North America has shown a significant interest in NASH research and drug development. This engagement has led to clinical trials, investments, and collaborations to bring NASH therapies to market.

Key Market Players

Intercept Pharmaceuticals Inc.

Galmed Research & Development Ltd.

INVENTIVA S.A.

AbbVie Inc.

Galectin Therapeutics Inc.

Madrigal Pharmaceuticals Inc.

NGM Biopharmaceuticals Inc.

Novo Nordisk A/S

Bristol Myers Squibb

Gilead Sciences Inc.

Report Scope:

In this report, the Global Non-Alcoholic Steatohepatitis Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Non-Alcoholic Steatohepatitis Treatment Market, By Drug Type:

    Vitamin E and Pioglitazone Obeticholic Acid (OCA) Lanifibranor Semaglutide Resmetirom Aramchol Cenicriviroc Others

Non-Alcoholic Steatohepatitis Treatment Market, By End-User:

    Hospital Pharmacies Retail and Specialty Pharmacies Others

Non-Alcoholic Steatohepatitis Treatment Market, By Region:

    North America
    • United States
    • Canada
    • Mexico
    Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
    Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    South America
    • Brazil
    • Argentina
    • Colombia
    Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Non-Alcoholic Steatohepatitis Treatment Market.

Available Customizations:

Global Non-Alcoholic Steatohepatitis Treatment market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Impact of COVID-19 on Global Non-Alcoholic Steatohepatitis Treatment Market

5. Voice of Customer

6. Global Non-Alcoholic Steatohepatitis Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Type (Vitamin E and Pioglitazone, Obeticholic Acid (OCA), Lanifibranor, Semaglutide, Resmetirom, Aramchol, Cenicriviroc, Others)
    • 6.2.2. By End User (Hospital Pharmacies, Retail and Specialty Pharmacies, Others)
    • 6.2.3. By Region
    • 6.2.4. By Company (2023)
  • 6.3. Market Map

7. Asia Pacific Non-Alcoholic Steatohepatitis Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Type
    • 7.2.2. By End User
    • 7.2.3. By Country
  • 7.3. Asia Pacific: Country Analysis
    • 7.3.1. China Non-Alcoholic Steatohepatitis Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Type
        • 7.3.1.2.2. By End User
    • 7.3.2. India Non-Alcoholic Steatohepatitis Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Type
        • 7.3.2.2.2. By End User
    • 7.3.3. Australia Non-Alcoholic Steatohepatitis Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Type
        • 7.3.3.2.2. By End User
    • 7.3.4. Japan Non-Alcoholic Steatohepatitis Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Type
        • 7.3.4.2.2. By End User
    • 7.3.5. South Korea Non-Alcoholic Steatohepatitis Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Type
        • 7.3.5.2.2. By End User

8. Europe Non-Alcoholic Steatohepatitis Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Type
    • 8.2.2. By End User
    • 8.2.3. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Non-Alcoholic Steatohepatitis Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Type
        • 8.3.1.2.2. By End User
    • 8.3.2. Germany Non-Alcoholic Steatohepatitis Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Type
        • 8.3.2.2.2. By End User
    • 8.3.3. Spain Non-Alcoholic Steatohepatitis Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Type
        • 8.3.3.2.2. By End User
    • 8.3.4. Italy Non-Alcoholic Steatohepatitis Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Type
        • 8.3.4.2.2. By End User
    • 8.3.5. United Kingdom Non-Alcoholic Steatohepatitis Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Type
        • 8.3.5.2.2. By End User

9. North America Non-Alcoholic Steatohepatitis Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Type
    • 9.2.2. By End User
    • 9.2.3. By Country
  • 9.3. North America: Country Analysis
    • 9.3.1. United States Non-Alcoholic Steatohepatitis Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Type
        • 9.3.1.2.2. By End User
    • 9.3.2. Mexico Non-Alcoholic Steatohepatitis Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Type
        • 9.3.2.2.2. By End User
    • 9.3.3. Canada Non-Alcoholic Steatohepatitis Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Type
        • 9.3.3.2.2. By End User

10. South America Non-Alcoholic Steatohepatitis Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Type
    • 10.2.2. By End User
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Non-Alcoholic Steatohepatitis Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Type
        • 10.3.1.2.2. By End User
    • 10.3.2. Argentina Non-Alcoholic Steatohepatitis Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Type
        • 10.3.2.2.2. By End User
    • 10.3.3. Colombia Non-Alcoholic Steatohepatitis Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Type
        • 10.3.3.2.2. By End User

11. Middle East and Africa Non-Alcoholic Steatohepatitis Treatment Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Drug Type
    • 11.2.2. By End User
    • 11.2.3. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Non-Alcoholic Steatohepatitis Treatment Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Drug Type
        • 11.3.1.2.2. By End User
    • 11.3.2. Saudi Arabia Non-Alcoholic Steatohepatitis Treatment Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Drug Type
        • 11.3.2.2.2. By End User
    • 11.3.3. UAE Non-Alcoholic Steatohepatitis Treatment Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Drug Type
        • 11.3.3.2.2. By End User

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

  • 13.1. Recent Developments
  • 13.2. Product Launches
  • 13.3. Mergers & Acquisitions

14. Global Non-Alcoholic Steatohepatitis Treatment Market: SWOT Analysis

15. Porter's Five Forces Analysis

  • 15.1. Competition in the Industry
  • 15.2. Potential of New Entrants
  • 15.3. Power of Suppliers
  • 15.4. Power of Customers
  • 15.5. Threat of Substitute Product

16. PESTLE Analysis

17. Competitive Landscape

  • 17.1. Intercept Pharmaceuticals Inc
    • 17.1.1. Business Overview
    • 17.1.2. Product & Service Offerings
    • 17.1.3. Recent Developments
    • 17.1.4. Key Personnel
    • 17.1.5. SWOT Analysis
  • 17.2. Galmed Research & Development Ltd.
  • 17.3. INVENTIVA S.A.
  • 17.4. AbbVie Inc.
  • 17.5. Galectin Therapeutics Inc.
  • 17.6. Madrigal Pharmaceuticals Inc.
  • 17.7. NGM Biopharmaceuticals Inc.
  • 17.8. Novo Nordisk A/S
  • 17.9. Bristol Myers Squibb
  • 17.10. Gilead Sciences Inc

18. Strategic Recommendations